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We report the expression of the human muscle (CK-MM) and brain (CK-BB) creatine kinases
in Escherichia coli.The proteins have been purified to apparent homogeneity and several of
their physical and kinetic properties investigated. In the process, we have conclusively veri-
fied the correct DNA sequence of the genes encoding the respective isozymes, and determined
the correct primary structure and mass of the gene products. Alignment of the primary se-
quences of these two enzymes shows 81% sequence identity with each other, and no obvious
gross structural differences. However, Western blot analyses demonstrated the general lack of
antigenic cross-reactivity between these isozymes. Preliminary kinetic analyses show the Km
and kcat values for the creatine and MgATP substrates are similar to values reported for other
isozymes from various tissues and organisms. The human muscle and brain CKs do not, how-
ever, exhibit the synergism of substrate binding that is observed, for example, in rabbit mus-
cle creatine kinase.
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1. INTRODUCTION
Creatine kinase (CK; ATP:creatine N-phosphotrans-
ferase; EC 2.7.3.2)4 catalyzes the reversible transfer of
the γ-phosphoryl group of MgATP to creatine, result-
ing in the formation of phosphocreatine and MgADP.
The enzyme plays a key role in cell energy metabolism
(Watts, 1973) as well as in the transport of “high en-
ergy phosphates” (Jacobus, 1985). CK is a important
clinical marker for a number of disease states includ-
ing myocardial infarction (Wu, 1989) and muscular
dystrophy (Gruemer and Prior, 1987).
The enzyme is most common in muscle and brain
cells, although smaller amounts are found in other tis-
sues. There are two cytosolic creatine kinase subunits,
brain (B) and muscle (M), which associate to form the
muscle (MM) and brain (BB) isozymes. In addition
there is a heterodimeric isozyme (MB), and it is ele-
vated levels of this form of the enzyme which are used
as a marker for myocardial infarction. Finally, there are
two forms of the enzyme associated with the inner
membrane of mitochondria. These are referred to as the
sarcomeric (Mis) and ubiquitous (Miu) isozymes and
may exist either as dimers or octamers. Depending on
the conditions, these forms are readily interconvertible
(Mühlebach et al.,1994), but, unlike the cytosolic CKs,
no heteromers have been found i  vivo.
Creatine kinase cDNAs, from species ranging from
sea urchins to dogs, have been cloned and sequenced
with considerable sequence homology being observed
(Babbitt et al., 1986; Mühlebach et al., 1994). Human
4 Abbreviations: CK, creatine kinase; HMCK, human muscle creatine
kinase; HBCK, human brain creatine kinase; CK-MM, creatine ki-
nase muscle isozyme; CK-BB, creatine kinase brain isozyme; PMSF,
phenylmethylsulfonyl fluoride; DTT, dithiothreitol; IEF, isoelectric
focusing; SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel
electrophoresis.
muscle (Perryman et al.,1986), human brain (Mariman
et al.,1989; Villareal-Levy et al.,1987), and human mi-
tochondrial (Haas and Strauss, 1990) cDNAs have all
been cloned and sequenced. Predictably, all show a high
degree of homology, with each encoding a protein of
about 40 kDa. Recently, the human brain (HBCK) and
human muscle (HMCK) isozymes have been expressed,
at low levels, in CHO cells and some preliminary ki-
netic data obtained (Lin et al.,1994). In order to obtain
sufficient quantities of these human CK isozymes for
X-ray studies, we have developed an system wherein
both HMCK and HBCK are expressed at high levels in
E. coli. This paper describes the expression and purifi-
cation of these enzymes and compares their kinetic
properties to the corresponding enzyme obtained from
tissue preparations.
2. MATERIALS AND METHODS
2.1. Materials
Restriction and DNA modifying enzymes were
purchased from Boehringer Mannheim and New Eng-
land Biolabs. Reagents and enzymes for DNA amplifi-
cation were purchased from Perkin-Elmer/Cetus and
Stratagene. The plasmid vector, pET17b, was purchased
from Novagen, Inc., while the bacterial strains, DH5α
and BL21(DE3)pLysS, were obtained from BRLGibco
and Novagen, respectively. Bacterial media was pre-
pared using materials purchased from Difco. DNA se-
quencing of the human muscle and human brain CK
cDNA was carried out by the dideoxy method (Sanger
et al.,1977) with the Sequenase kit (U.S. Biochemical),
utilizing oligonucleotides synthesized by the Biomolec-
ular Resource Center (University of California, San
Francisco). Electrophoresis and protein assay reagents
were from Bio-Rad and Amersham Pharmacia Biotech.
All other reagents were of the highest quality available.
2.2. Subcloning of Human CK cDNA into the
pET17/CK7 Vector
2.2.1. Human Muscle CK
A pET17b construct, containing rabbit muscle cre-
atine kinase from pKTMCK (Chen et al., 1991), was
prepared and denoted pET17b/CK7 (Chen et al.,1996).
This construct contained a Sal1 site, downstream of the
Nde1 site in pET17b.
The cDNA-derived HMCK gene, cloned into the
mammalian expression vector pSG5 (Lin et al.,1994),
was obtained from Dr. M. B. Perryman (University of
Colorado). The polymerase chain reaction (PCR) was
used to engineer an NdeI restriction site (CATATG) at
the initiating methionine and a SalI site (GTCGAC)
downstream of the 3′ terminus of the HMCK gene. The
PCR was carried out on a Perkin Elmer/Cetus DNA
Thermal Cycler 480 using 25 ng of dsDNA and 25 pmol
of each oligonucleotide primer. Initially, the DNA was
denatured at 94°C for 1 min, followed by a hybridiza-
tion at 30°C for 1 min, and then extension at 72°C for
2 min. This was carried out for a total of five cycles,
after which the hybridization temperature was elevated
to 60°C to increase the stringency of amplification,
and the amplification continued for 30 cycles. The am-
plified products were purified with glass beads from
the USBioclean Kit (U.S. Biochemicals) as per the
manufacturer’s instruction. The PCR product contain-
ing the HMCK gene with the new Nde1 and SalI sites
was then digested with these enzymes, purified, and
ligated into the pET17b/CK7 vector, which had been
similarly digested. The resulting construct, containing
the HMCK gene, was designated pETHMCK and is
shown with pertinent restriction sites in Fig. 1A.
2.2.2. Human Brain CK
A plasmid containing the human brain CK cDNA
(Villareal-Levy et al., 1987) was also obtained from
Dr. M. B. Perryman. In order to insert the cDNA into
the pET17b/CK7 vector, NdeI and SalI restriction sites
were engineered into the 5′ and 3′ ends of the gene as
described for the human muscle CK gene. Subsequent
restriction digests and ligation steps were also carried
out as for the muscle gene. The resulting construct,
shown in Fig. 1B, was designated pETHBCK.
2.3. Expression of Human Muscle and Brain
Creatine Kinase
E. coli cells, BL21 (DE3)pLysS, made competent
either by calcium chloride treatment (Dagert and Er-
lich, 1979) or by the procedure of Hanahan (Hanahan,
1983), were transformed with the appropriate pET
construct and plated on LB/ampicillin/choramphenicol
at 37°C. A single colony was picked from this plate
and grown overnight in liquid LB/Ap/Cm medium at
37°C. The cells were pelleted, resuspended in fresh
media, and used to inoculate 1 L of LB/Ap/Cm. After
the culture had reached a cell density of A600 ≈ 1.8, the
cells were cooled to 30°C, then induced with 0.5 mM
IPTG. Cells were harvested 4 h postinduction.
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2.4. CK Purification
2.4.1. Human Muscle CK
The purification scheme for the isolation of
human muscle CK from E. coli was a modification of
that described by Chen et al. (1991) for the purifica-
tion of rabbit muscle creatine kinase. The cells were
resuspended in buffer A (10 mM MES, 20 mM KCl,
0.1 mM PMSF, 1 mM DTT, pH 6.0). Cell lysis was
achieved either by sonication (Ultrasonics Inc.) or by
mixing with glass beads in a Beadbeater apparatus
(BioSpec Products). In the previously published pro-
cedure, a 50%–75% ethanol fractionation step was in-
cluded at this point. However, the ethanol fractiona-
tion was found to be too harsh a treatment for some of
the CK isozymes, resulting in lower yields. The levels
of CK expression were sufficiently high to allow us to
bypass this step with no significant loss in activity or
yield (data not shown). The lysed cells were cen-
trifuged at 12,000 × g for 20 min, and the supernatant,
containing the HMCK, was loaded directly onto a
Blue-Sepharose 4B column (Amersham Pharmacia
Biotech). After washing with 4–5 column volumes of
buffer A, the enzyme was eluted with buffer B (10 mM
TES, 1 mM DTT, 20 mM DTT, 20 mM KCl, 0.1 mM
PMSF, pH 8.0). The eluted HMCK was concentrated
and dialyzed against 50 mM TrisCl, pH 8.8, prior to
application to MonoQ HR 10/10 column (Pharmacia
Biotech). A linear NaCl gradient (0–100 mM, in the
same buffer), was then introduced resulting in the elu-
tion of >99% pure HMCK at ∼ 30 mM NaCl. The puri-
fied enzyme was stored at −20°C in 50 mM HEPES,
0.1 mM EDTA, 1 mM DTT, pH 7.0.
2.4.2. Human Brain CK
Cell lysis and initial chromatography over Blue
Sepharose 4B was performed as described above for
HMCK. The eluted sample was equilibrated in 50 mM
TrisCl, pH 7.5, prior to chromatography over MonoQ
HR 10/10 column. After washing in the same buffer, a
0–0.5M NaCl gradient was introduced, with the HBCK
eluting at approximately 140 mM NaCl. Two peaks of
equivalent specific activities were isolated, the latter
containing >99% pure HBCK. Again, the purified en-
zyme was stored at −20°C in 50 mM HEPES, 0.1 mM
EDTA, 1 mM DTT, pH 7.0.
2.5. SDS–PAGE, IEF–PAGE, and Western Blots
Protein samples were subjected to electrophoresis
on a 12% SDS–polyacrylamide gel (Novex, San Diego,
CA). Isoelectric focusing of CK isozymes was perfor-
med using a 5% nondenaturing polyacrylamide gel (pH
3–10, Novex) on a FBE-3000 Flat Bed Apparatus (Phar-
macia) in accordance with manufacturer’s instructions.
The gels were prefocused for 1.5 h, the samples applied,
and electrofocusing continued for an additional 2.5 h.
The gel was fixed in a mixture of 5% sulfosalicylic acid
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Fig. 1. Restriction maps of pETHMCK and pETHBCK used for the expression of human muscle and human brain
creatine kinase, respectively. With the exception of the Nd 1 and Sal1 sites, used in the cloning procedures, the
restriction sites shown are unique to each vector.
and 10% trichloroacetic acid before staining in 0.1%
Coomassie blue R250.
Primary antibodies raised against the human mus-
cle and brain CK in goat were purchased from Cortex
Biochem., Inc., and alkaline phosphatase-conjugated
secondary antibodies were obtained from Jackson Im-
munoResearch Laboratories, Inc. Other blotting re-
agents were purchased from Bio-Rad and used as per
the manufacturer’s instructions.
Western blotting was carried out using a Genie
Electrophoretic Blotter (Idea Scientific Co.). Follow-
ing 12.5% SDS–PAGE, samples of the purified CK
isozymes (10 µg) were electrotransferred onto nitro-
cellulose. The nitrocellulose was then equilibrated in
blocking buffer, 1% milk powder in 1× Tris-buffered
saline +0.1% Tween 20 (1× TTBS) for 1 h at room
temperature. After washing for 10 min with TTBS, one
nitrocellulose strip containing both muscle and brain
CKs was incubated for 1 h with a 1:500 dilution of
goat α-human brain CK antiserum. A second strip was
incubated with goat α-human muscle CK purified IgG
at a concentration of 1:5000 in blocking buffer. The ni-
trocellulose strips were then washed with Tris-buffered
saline +0.1% Tween 20, prior to incubation with the
secondary rabbit α-goat FC conjugated to alkaline
phosphatase. The blots were washed again for 3 × 5 min
in TTBS, before development with the alkaline phos-
phatase conjugate substrate kit.
2.6. Mass Spectrometry
Human muscle and brain CKs, prepared as 20 µM
solutions in methanol/water/acetic acid, were subjected
to electrospray analysis on a modified Extrel Waters
FTMS-2000 as described previously (Wood et al.,
1995a).
2.7. Enzyme Assays and Other Methods.
Absorbance measurements were carried out on a
Hewlett-Packard 8452A diode-array spectrophotome-
ter. Protein concentrations were determined using a
modified Bradford assay (Bradford, 1976), with bovine
serum albumin as the protein standard (Pierce). In ad-
dition, an extinction coefficient (ε280(0.1%)) of 0.88
(Cleland, 1979; Kuby et al., 1962) was used to deter-
mine protein concentrations of the pure enzyme sam-
ples. Creatine kinase activity was determined either by
the coupled assay system of Tanzer and Gilvarg (1959)
or by a pH-stat (Radiometer Copenhagen) assay. De-
termination of the kinetic constants was carried out
under the buffer conditions of Morrison and James
(1965), and the data analyzed with the programs of
Cleland (1979).
3. RESULTS AND DISCUSSION
3.1. DNA Sequence Verification
In the literature, two different DNA sequences for
the human muscle creatine kinase gene have been re-
ported (Perryman et al., 1986; Trask et al., 1988). In
the latter report, several possible errors in the Perry-
man et al.(1986) gene sequence were alluded to. These
discrepancies resulted in the following changes in the
amino acid sequence: Ile47Thr (whereby the Perryman
sequence translated to an isoleucine,and the Trask se-
quence suggested threonine), P130R, Q193L, H210D,
P215R, and AM324G. Alignment of the primary se-
quence of several CK isozymes and other structural
homologs (Mühlebach et al.,1994) also suggest possi-
ble errors in the Perryman et al. (1986) sequence. For
instance, threonine is a conserved residue in all mus-
cle, brain, and mitochondrial CK sequences at position
47. Similarly, R130, L193, D210, R215, and G324, are all
highly conserved residues. While the conservation of
these residues across several creatine kinase isozymes
does not preclude the existence of other amino acid
residues at those positions in HMCK, it does suggest
that the Trask et al. (1988) sequence is more likely to
be correct.
Two DNA sequences have also been reported
for the human brain isozyme (Mariman et al., 1989;
Villareal-Levy et al.,1987). Again, both sequences are
at odds, with the discrepancies arising at several posi-
tions that show significant GC compressions. These
base changes result in the translation of different
amino acid residues in the human brain CK. Once
again, an alignment of several CK and structural
analogs was valuable for suggesting what may be the
correct sequence. Such an analysis revealed that sev-
eral of the residues are highly conserved and suggests
that the original sequence (Villareal-Levy et al.,1987)
may be in error. These residues include Leu41 (which
was previously translated as a valine), Gly97 (Arg),
Gly98 (Arg), His105 (Asp), Arg131 (Ala), Arg214 (Ala),
Gly215 (Arg), and His295 (Asp).
In light of these discrepancies, we have determined
the DNA sequence of the human muscle CK gene, both
in pGS5 (Lin et al.,1994), as well as that in our E. coli
expression construct pETHMCK. The results from both
vectors were identical and are fully consistent with the
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3.2. Purification and Characterization of
Recombinant CK Isozymes
A simple, two-step purification scheme, which
was essentially a modification of that used for rabbit
muscle CK (Chen et al.,1991), was developed for both
isozymes. Following cell lysis and removal of insolu-
ble cellular debris, the enzyme was purified by chro-
matography over Blue-Sepharose, followed by chro-
matography over a MonoQ resin. Figure 3 shows
the SDS–PAGE analysis of a typical purification of
ΗBCK and provides an indication of the purity of the
final product The high yield of CK per liter of culture
media allows us to bypass the ethanol precipitation
step used in earlier creatine kinase purification schemes
(Chen et al., 1991; Kuby et al., 1954; White et al.,
1992). With the current purification scheme, routine
yields of 15–20 mg pure enzyme/L of culture were ob-
tained for the HBCK isozyme, while even higher
yields of 50–75 mg/L were obtained for the HMCK
preparations.
Both rabbit muscle (Chen et al.,1991; Maggio and
Kenyon, 1977) and rabbit brain (Armstrong et al.,1977)
creatine kinase appear to be predisposed toward forma-
tion of sample microheterogeneity. Indeed, the hetero-
geneity of some isozymes has been used as a diagnostic
marker in various disease states (Apple, 1989). It was
Human Muscle and Brain CKs expressed in E. coli 63
sequence of Trask et al. (1988). We also determined
the DNA sequence of the cDNA-derived gene encod-
ing the human brain CK isozyme from the original
construct (Villareal-Levy et al.,1987), as well as from
our E. coli expression plasmid, pETHBCK. Again, the
DNA sequences that we obtained from both of these
constructs are identical and are consistent with the
gene sequence derived from the genomic DNA by Ma-
riman et al. (1989).
The correct translation of both human muscle and
brain creatine kinase genes is shown in Fig. 2. The
amino acid sequences demonstrate the high degree
of homology that exists between the two isozymes
(81%). However, the degree of homology is even more
striking when the CK muscle isozymes are compared
to one another, or when the brain isozymes are com-
pared with one another (Babbitt e al., 1986; Mühle-
bach et al., 1994). Human and rabbit muscle creatine
kinases, for example, are about 95% identical (Babbitt
et al.,1986).
The amino acid sequence of HMCK (Fig. 2)
translates to a protein with a predicted subunit MW
of 43,098 Da, whereas the sequence of Perryman 
et al. (1986) yields a predicted subunit MW of 42,911
Da. The observed mass of the cDNA-derived HMCK,
as determined by Fourier transform mass spec-
trometry utilizing an electrospray ionization source
(McLafferty, 1995; Wood et al., 1995a), was shown
to be 42,969 ± 2 Da. This is consistent with the
HMCK sequence in Fig.2, lacking its N-terminal me-
thionine residue (42,968 Da). Similarly, the predicted
MW of HBCK from the Villareal-Levy et al. (1987)
studies is 42,622 Da, whereas that derived from 
the sequence of Mariman et al. (1989) is 42,512 Da.
The observed mass of the cloned, E. coli-expressed
HBCK was shown to be 42,513 ± 2 Da. Thus, the ob-
served masses of both the human muscle and the
brain CK isozymes, overexpressed in a soluble form
in E. coli, are consistent with the masses of the pre-
dicted proteins translated from the respective genes.
In addition, these mass spectrometry results show
that the PCR amplification and subsequent sub-
cloning of the genes into an E. coli expression vector
did not compromise the integrity of the resultant gene
product.
Overall, the results from our independent DNA
sequence determination of both CK genes and the
mass spectral analyses on the purified proteins provide
separate and distinct evidence for suggesting which
DNA sequences correctly encode the brain CK (Mari-
man et al.,1989) and the muscle CK isozymes (Trask
et al.,1988).
Fig. 2. Amino acid sequence of (A) human muscle and (B) human
brain creatine kinase.
suggested that the multiple forms may arise as artifacts
of the purification (Chen et al.,1991), and it was of in-
terest to determine whether removal of the ethanol pre-
cipitation step would reduce the level of heterogeneity.
Figure 4 shows a 5% isoelectric focusing gel of MonoQ-
purified samples of the human brain and muscle iso-
zymes. Both samples demonstrate significant hetero-
geneity. Using the sequence data shown in Fig. 2, the
isoelectric point (pI) of human brain CK is predicted to
be 5.37. However, the gel shows that there at least two
major isoforms, with isoelectric points ranging from 4.9
to 5.4. Similarly, the predicted pI of human brain CK is
7.26. For the latter isozyme, the gel is even more strik-
ing, as a family of at least four isoforms with pI ranging
from 6.9 to 7.8 can be seen. As in the case of the rab-
bit muscle CK, these isoforms were found regardless
of the protein source (tissue-purified or expressed in E.
coli), and all of the various isoforms were shown to
have CK activity using a CK activity stain (White,
1996). Clearly the ethanol precipitation step, while it
may have an influence on the overall yield of the pu-
rification, is not the sole source of the heterogeneity,
and it is likely that deamidation is playing a significant
role (Wood et al.,1995b). This possibility is currently
being investigated.
Despite their considerable sequence homology,
there are significant differences between the brain and
muscle isozymes. In addition to the IEF described
above, experiments were also carried out to determine
the level of antigenic cross-reactivity between the two
isozymes. The results are shown in Fig. 5. In the first
panel, primary antibodies to tissue-purified human
muscleCK were reacted with purified, recombinant,
human muscle and brain CK samples. The second
panel shows the converse experiment, wherein anti-
bodies raised against tissue-purified human brain CK
are reacted with recombinant CK samples identical to
those in the first panel. The most immediate result is
that the antibodies raised against the tissue-purified
enzyme recognize the E. coli-expressed samples, and
therefore any possible posttranslational modifications
of CK are not essential for antigenic recognition. Fur-
ther, it demonstrates that the brain and muscle iso-
zymes are immunologically distinct. This is consistent
with previous work in our laboratory using salmon
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Fig. 3. SDS–PAGE analysis of recombinant human brain CK-BB
protein samples after each purification step. Lane 1: Novex low-
molecular-weight markers; lane 2: crude cell extract of induced BL21
(DE3)/pETHBCK; lane 3: CK-containing fraction after TES buffer
elution of Blue Sepharose column; lane 4: after MonoQ column.
Fig. 4. Native IEF–PAGE (pH 3–10) analysis of recombinant human
brain and human muscle CK isozymes. IEF standards (Novex) and
CK isozymes (10 µg) were stained with Coomassie blue R250. Lane
1: IEF standards; lane 2: human brain CK-BB; lane 3: human muscle
CK-MM.
contamination present in the tissue-purified brain CK
used as the antigen for the production of the α-CK an-
tibodies used in our Western blot analysis. Finally,
polyclonal antibodies raised to recombinant CK-BB
appeared to have identical cross-reactivity to recombi-
nant brain CK as the antibodies raised against CK-BB
purified from tissue (data not shown). This suggests
that recombinant CK antigens may be acceptable for
the purpose of generating α-CK antibodies for clinical
or diagnostic use.
3.3. Kinetic Analysis
An initial kinetic analysis of the CK-MM and CK-
BB isozymes was carried out for the reaction in the
forward direction, i.e., formation of phosphocreatine
and ADP. The data were obtained at pH 9.0, a pH
value at which creatine kinase is expected to have a
rapid equilibrium random bi–bi mechanism (Kenyon
and Reed, 1983). The results are presented in Table I.
The observed kinetic constants for both brain and mus-
cle isozymes are similar to those reported for the rab-
bit muscle isozyme (Maggio and Kenyon, 1977), as
well as for the human and brain isozymes expressed and
isolated from COS cells (Lin et al.,1994). Jacobs and
Kuby (1980) carried out an analysis of autopsy tissue-
purified CK-BB and CK-MM at pH 8.8 and, for com-
parison, their results are also shown  in Table I. The
Vmax and Km values are broadly in agreement, although
the Km value for the tissue-purified brain isozyme is
marginally lower than that of its recombinant counter-
part. It is not clear whether this difference is due to
sample preparation or possibly to posttranslational
modifications unique to the brain isozyme, such as
phosphorylation (Chida et al.,1990; Quest et al.,1990;
Wallimann et al.,1992), which may have an effect on
substrate binding.
It has been shown that the rabbit muscle CK ex-
hibits synergism in the binding of the substrates, i.e.,
that the binding of the first substrate enhances the bind-
ing of the second substrate (Maggio and Kenyon, 1977;
Morrison and James, 1965). It has been suggested
that the synergism may be associated with substrate-
induced conformational changes within the tertiary
complex. The synergy can be identified by a decrease
in Km as compared to Ks for each substrate. The kinetic
studies described here were carried out under condi-
tions identical to those of Maggio and Kenyon (1977),
who reported a threefold decrease in Km vs. Ks for both
creatine and MgATP. The results in Table I show that
both Km and Ks are similar for each of the recombinant
human isozymes and indicate that neither of these
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Fig. 5. Immunologic crossreactivity of recombinant human brain and
muscle creatine kinase with antibodies raised against tissue-purified
human CKs. Aliquots (10 µg) of purified recombinant human muscle
(M) and human brain (B) creatine kinase were electrophoresed on
12.5% SDS–PAGE. After electroblotting with nitrocellulose the blot
was cut in half. One half of the blotted protein was treated with α-
brain CK antibodies and the other half was treated with α-muscle
antibodies, as described in Materials and Methods.
brain and muscle CK (White t al., 1992) as well as
observations from other laboratories (Armstrong et al.,
1977; Geng et al.,1989; Kato and Shimizu, 1986; Kato
et al., 1986). The figure also shows that, while the
polyclonal antibodies raised to muscle CK are specific
for the muscle isozyme, the antibodies raised against
brain CK show some cross-reactivity with the muscle
isozyme. Sensitive immunoassays using immobilized
F(ab′)2 fragments of monospecific antibodies to both
brain and muscle CK isozymes were found to have
completely isozyme-specific recognition patterns (Kato
and Shimizu, 1986, 1987; Kato et al.,1986). The slight
degree of cross-reactivity observed in our experiments
may be due to a small amount of isozyme cross-
isozymes appears to exhibit this synergism. Conversely,
the Km values of the tissue-purified CKs are signifi-
cantly lower than the Ks values. Again it is not clear
whether these differences are due to artifacts due to the
purification process or possibly posttranslational mod-
ifications. Further studies aimed at full physical and ki-
netic characterization of the recombinant proteins are
continuing in our laboratory.
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Table I. Comparison of Kinetic Constants for Recombinant and Tissue-Derived
Creatine Kinasesa
Recombinant Tissue Recombinant Tissue
HBCK HBCKb HMCK HMCK b
KaCr 6.0 ± 0.3 17 ± 2 14.6 ± 1.2 49 ± 14
KmCr 4.9 ± 0.4 2.5 ± 0.1 9.5 ± 0.59 19 ± 2
KaMgATP 0.99 ± 0.05 0.66 ± 0.04 1.2 ± 0.11 0.63 ± 0.05
KmMgATP 0.81 ± 0.10 0.10 ± 0.01 0.89 ± 0.16 0.26 ± 0.08
kcat(min
−1) 12.9 × 103 7.15 × 103 9.21 × 103 8.67 × 103
a Concentrations are expressed in mM.
b From Jacobs and Kuby (1980).
